NO20004781L - Svekkede bakterier anvendelige i vaksiner - Google Patents

Svekkede bakterier anvendelige i vaksiner

Info

Publication number
NO20004781L
NO20004781L NO20004781A NO20004781A NO20004781L NO 20004781 L NO20004781 L NO 20004781L NO 20004781 A NO20004781 A NO 20004781A NO 20004781 A NO20004781 A NO 20004781A NO 20004781 L NO20004781 L NO 20004781L
Authority
NO
Norway
Prior art keywords
vaccines
attenuated bacteria
useful
bacteria useful
gene
Prior art date
Application number
NO20004781A
Other languages
English (en)
Other versions
NO20004781D0 (no
NO327609B1 (no
Inventor
Steven Neville Chatfield
Original Assignee
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptide Therapeutics Ltd filed Critical Peptide Therapeutics Ltd
Publication of NO20004781D0 publication Critical patent/NO20004781D0/no
Publication of NO20004781L publication Critical patent/NO20004781L/no
Publication of NO327609B1 publication Critical patent/NO327609B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C12N15/03—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Abstract

Bakterie som er blitt svekket ved en ikke-reverserende mutasjon i aroC-genet, ompF-genet og ompC-genet. Bakterien er nyttig som vaksine. Bakterien kan f.eks. være en svekket stamme av E. coli som er nyttig ved vaksinasjon mot diaré.
NO20004781A 1998-03-25 2000-09-25 Svekkede muterte bakterier anvendelige i vaksiner. NO327609B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9806449.6A GB9806449D0 (en) 1998-03-25 1998-03-25 Attenuated bacteria useful in vaccines
PCT/GB1999/000935 WO1999049026A1 (en) 1998-03-25 1999-03-25 Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines

Publications (3)

Publication Number Publication Date
NO20004781D0 NO20004781D0 (no) 2000-09-25
NO20004781L true NO20004781L (no) 2000-11-08
NO327609B1 NO327609B1 (no) 2009-08-31

Family

ID=10829280

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004781A NO327609B1 (no) 1998-03-25 2000-09-25 Svekkede muterte bakterier anvendelige i vaksiner.

Country Status (19)

Country Link
US (1) US6902906B1 (no)
EP (1) EP1066376B1 (no)
JP (1) JP4516210B2 (no)
KR (1) KR100628657B1 (no)
AT (1) ATE296881T1 (no)
AU (1) AU763683B2 (no)
CA (1) CA2323576C (no)
CZ (1) CZ301520B6 (no)
DE (1) DE69925585T2 (no)
DK (1) DK1066376T3 (no)
ES (1) ES2244182T3 (no)
GB (1) GB9806449D0 (no)
HU (1) HU225644B1 (no)
NO (1) NO327609B1 (no)
NZ (1) NZ507077A (no)
PL (1) PL196076B1 (no)
PT (1) PT1066376E (no)
WO (1) WO1999049026A1 (no)
ZA (1) ZA200004987B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138237B1 (en) 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
WO2002057780A1 (en) 2001-01-18 2002-07-25 Newcastle University Ventures Ltd. Biosensor with covalently attached membrane-spanning proteins
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
US7297338B2 (en) * 2003-05-14 2007-11-20 Wyeth Avian vaccine composition for the protection of poultry against disease and infection caused by E. coli and Salmonella
US7357935B2 (en) * 2003-05-14 2008-04-15 Wyeth Avian E. coli vaccine for protection against colibacillosis
CN101378780A (zh) * 2006-02-01 2009-03-04 Sbl疫苗公司 重组细菌中的肠产毒性大肠杆菌定居因子(cf)抗原
JP2008054614A (ja) * 2006-09-01 2008-03-13 Nippon Inst For Biological Science 鶏大腸菌由来弱毒変異株、鶏大腸菌対策用ワクチン、免疫方法及び鶏用ワクチンベクター
PL2066339T3 (pl) * 2006-09-18 2015-02-27 Univ Arkansas Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
WO2009059018A1 (en) * 2007-10-30 2009-05-07 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT3097926T (pt) 2007-11-01 2020-01-08 Univ Guelph Composições e métodos de potenciação das respostas imunitárias frente a eimeria
ES2643646T3 (es) 2010-01-21 2017-11-23 The Board Of Trustees Of The University Of Arkansas Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
MX350306B (es) 2010-06-09 2017-09-04 Univ Arkansas Vacuna y metodos para reducir una infeccion por campylobacter.
WO2014037445A1 (en) * 2012-09-05 2014-03-13 Lohmann Animal Health Gmbh Preparation of live vaccines
ES2776429T3 (es) 2012-12-07 2020-07-30 Elanco Tiergesundheit Ag Preparación de vacunas vivas
AR094791A1 (es) 2013-02-14 2015-08-26 Univ Arkansas Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria
AU2014239557B2 (en) 2013-03-15 2019-01-03 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
KR102767638B1 (ko) 2016-05-03 2025-02-20 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8730037D0 (en) 1987-12-23 1988-02-03 Wellcome Found Vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
ATE111957T1 (de) 1990-02-06 1994-10-15 Pasteur Institut Transformiertes shigella.
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
JP3415145B2 (ja) 1991-03-05 2003-06-09 ザ ウエルカム ファウンデーション リミテッド 弱毒化細菌における組換えタンパク質の発現

Also Published As

Publication number Publication date
PT1066376E (pt) 2005-10-31
JP4516210B2 (ja) 2010-08-04
WO1999049026A1 (en) 1999-09-30
AU763683B2 (en) 2003-07-31
HUP0105430A2 (hu) 2002-04-29
GB9806449D0 (en) 1998-05-27
EP1066376A1 (en) 2001-01-10
HU225644B1 (en) 2007-05-02
JP2002507414A (ja) 2002-03-12
CZ301520B6 (cs) 2010-03-31
NO20004781D0 (no) 2000-09-25
CA2323576A1 (en) 1999-09-30
EP1066376B1 (en) 2005-06-01
KR100628657B1 (ko) 2006-09-26
PL343246A1 (en) 2001-07-30
DK1066376T3 (da) 2005-10-03
CA2323576C (en) 2010-12-07
US6902906B1 (en) 2005-06-07
DE69925585D1 (de) 2005-07-07
KR20010042175A (ko) 2001-05-25
HUP0105430A3 (en) 2004-10-28
NZ507077A (en) 2002-10-25
NO327609B1 (no) 2009-08-31
ATE296881T1 (de) 2005-06-15
PL196076B1 (pl) 2007-12-31
AU3045899A (en) 1999-10-18
ES2244182T3 (es) 2005-12-01
CZ20003470A3 (cs) 2001-07-11
DE69925585T2 (de) 2006-07-13
ZA200004987B (en) 2001-10-31

Similar Documents

Publication Publication Date Title
NO20004781L (no) Svekkede bakterier anvendelige i vaksiner
KR937000640A (ko) 생 백신
ATE219948T1 (de) Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten
WO2001070247A3 (en) Salmonella vaccine materials and methods
DK0732937T4 (da) Ikke-toxisk slimhindeadjuvans
NO921729D0 (no) Stabile pura-vektorer og anvendelser derav
DE69713408D1 (de) Streptococcus equi Impstoff
DE60207277D1 (de) Bakterieller impfstoff
AU2002217043A1 (en) Salmonella vaccine
WO2000050074A3 (en) Neisserial vaccine compositions and methods
WO2007112518A8 (en) Live attenuated salmonella vaccine
Andoh et al. Comparative virulence of phase I and II Coxiella burnetii in immunodeficient mice
AU6992200A (en) Vaccines
Schwenteit et al. Construction of Aeromonas salmonicida subsp. achromogenes AsaP1‐toxoid strains and study of their ability to induce immunity in Arctic char, Salvelinus alpinus L.
WO2004089408A3 (en) Vaccine preparations comprising live or killed attenuated mutant neisseria bacteria
AU2001258579A1 (en) Virulence genes, proteins, and their use
HK1030016A (en) Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines
BR9809974A (pt) Vacinas vivas atenuadas
AU1853995A (en) Vaccine compositions
UA29201A (uk) Вакцинний штам бактерій bacillus anthracis сб-072 проти сибірки тварин
Hoiseth AROMATIC-DEFICIENT MUTANTS AS LIVE SALMONELLA VACCINES.
WO2002081676A3 (de) Nichtpathogener bakterieller rezipientenstamm eines mycolsäure-haltigen bakteriums, verfahren zu dessen herstellung und dessen verwendung
Stackebrandt et al. Myceligenerans
WO2000072803A3 (en) Streptococcus pneumoniae vaccine strain and uses thereof
UA33502A (uk) Спосіб виготовлення інактивованої вакцини проти сальмонельозів тварин

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees